OBJECTIVE: To review the current clinical evidence on the effects of corticosteroid interactions with the immunosuppressive drugs cyclosporine, tacrolimus, mycophenolate, and sirolimus. DATA SOURCES: Articles were retrieved through MEDLINE (1966-February 2008) using the terms corticosteroids, glucocorticoids, immunosuppressants, cyclosporine, tacrolimus, mycophenolate, sirolimus, drug interactions, CYP3A4, P-glycoprotein, and UDP-glucuronosyltransferases. Bibliographies were manually searched for additional relevant articles. STUDY SELECTION AND DATA EXTRACTION: All English-language studies dealing with drug interactions between corticosteroids and cyclosporine, tacrolimus, mycophenolate, and sirolimus were reviewed. DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. As a group, corticosteroids induce the CYP3A4 and P-gp pathways; however, a few exceptions exist and the impact on a patient's immunosuppressant regimen may be critical. Corticosteroids also have demonstrated an induction effect on the uridine diphosphate-glucuronosyltransferase enzymes and multidrug resistance-associated protein 2 involved in mycophenolate's disposition. Successful corticosteroid withdrawal regimens have been reported; however, only few studies have examined the effects of steroid withdrawal on the remaining immunosuppressive regimens. To date, the clinical impact of steroid withdrawal on disposition of other immunosuppressive agents is not well characterized, and reports of such drug-drug interactions are conflicting. CONCLUSIONS: While our understanding of the clinical impact of steroid-immunosuppressant interactions is limited, it remains a fact that corticosteroids have complex induction and inhibition interactions with common metabolic and transport pathways. Given the complex interaction of corticosteroids on crucial metabolic enzymes and transporter proteins, monitoring of immunosuppressive agents during steroid withdrawal is warranted to ensure optimal treatment outcomes.
OBJECTIVE: To review the current clinical evidence on the effects of corticosteroid interactions with the immunosuppressive drugs cyclosporine, tacrolimus, mycophenolate, and sirolimus. DATA SOURCES: Articles were retrieved through MEDLINE (1966-February 2008) using the terms corticosteroids, glucocorticoids, immunosuppressants, cyclosporine, tacrolimus, mycophenolate, sirolimus, drug interactions, CYP3A4, P-glycoprotein, and UDP-glucuronosyltransferases. Bibliographies were manually searched for additional relevant articles. STUDY SELECTION AND DATA EXTRACTION: All English-language studies dealing with drug interactions between corticosteroids and cyclosporine, tacrolimus, mycophenolate, and sirolimus were reviewed. DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. As a group, corticosteroids induce the CYP3A4 and P-gp pathways; however, a few exceptions exist and the impact on a patient's immunosuppressant regimen may be critical. Corticosteroids also have demonstrated an induction effect on the uridine diphosphate-glucuronosyltransferase enzymes and multidrug resistance-associated protein 2 involved in mycophenolate's disposition. Successful corticosteroid withdrawal regimens have been reported; however, only few studies have examined the effects of steroid withdrawal on the remaining immunosuppressive regimens. To date, the clinical impact of steroid withdrawal on disposition of other immunosuppressive agents is not well characterized, and reports of such drug-drug interactions are conflicting. CONCLUSIONS: While our understanding of the clinical impact of steroid-immunosuppressant interactions is limited, it remains a fact that corticosteroids have complex induction and inhibition interactions with common metabolic and transport pathways. Given the complex interaction of corticosteroids on crucial metabolic enzymes and transporter proteins, monitoring of immunosuppressive agents during steroid withdrawal is warranted to ensure optimal treatment outcomes.
Authors: Rachel J Ryu; Thomas R Easterling; Steve N Caritis; Raman Venkataramanan; Jason G Umans; Mahmoud S Ahmed; Shannon Clark; Ira Kantrowitz-Gordon; Karen Hays; Brooke Bennett; Matthew T Honaker; Kenneth E Thummel; Danny D Shen; Mary F Hebert Journal: J Clin Pharmacol Date: 2018-05-07 Impact factor: 3.126
Authors: Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson Journal: Br J Clin Pharmacol Date: 2011-12 Impact factor: 4.335
Authors: Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni Journal: Transplantation Date: 2011-02-15 Impact factor: 4.939
Authors: Catherine M T Sherwin; Anna Carmela P Sagcal-Gironella; Tsuyoshi Fukuda; Hermine I Brunner; Alexander A Vinks Journal: Br J Clin Pharmacol Date: 2012-05 Impact factor: 4.335
Authors: Rogier R Press; Bart A Ploeger; Jan den Hartigh; T van der Straaten; Hans van Pelt; Meindert Danhof; Hans de Fijter; Henk-Jan Guchelaar Journal: Eur J Clin Pharmacol Date: 2010-03-31 Impact factor: 2.953
Authors: P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani Journal: Eur J Clin Pharmacol Date: 2011-11-20 Impact factor: 2.953
Authors: Pamala A Jacobson; Jiayin Huang; Juan Wu; Miae Kim; Brent Logan; Amin Alousi; Michael Grimley; Javier Bolaños-Meade; Vincent Ho; John E Levine; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-03 Impact factor: 5.742